Joseph Forester, DO
Allergy & Immunology · Cullman, ALNPI 1972520658
Payments from drug & device makers
Across 1,007 payments — averaging $714.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$601K
- Merck$64K
- Genentech USA, Inc.$20K
- Amgen$11K
- ARS Pharmaceuticals Operations, Inc.$11K
- Pfizer$6K
- plus $5K from 22 others
What the payments were for
- Consulting fees$4,5511%
- Speaking & faculty fees$618,98586%
- Travel & lodging$76,80911%
- Food & beverage$18,4803%
- Education$2190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 749 | $601,446 |
| Merck | 44 | $63,967 |
| Genentech USA, Inc. | 30 | $19,887 |
| Amgen | 24 | $11,450 |
| ARS Pharmaceuticals Operations, Inc. | 31 | $10,798 |
| Pfizer | 7 | $6,200 |
| Sanofi | 17 | $2,692 |
| Regeneron Healthcare Solutions, Inc. | 32 | $910 |
| GSK | 17 | $342 |
| CSL Behring | 9 | $269 |
| Novartis | 10 | $210 |
| Sanofi-aventis U.S. LLC | 2 | $123 |
| Blueprint Medicines Corporation | 4 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| GC Biopharma USA, Inc. | 5 | $91 |
| Galderma Laboratories, L.p. | 3 | $59 |
| Insmed, Inc. | 2 | $57 |
| Cycle Pharmaceuticals Inc | 2 | $54 |
| Grifols USA, LLC | 2 | $53 |
| Johnson & Johnson | 3 | $52 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Organon | 2 | $29 |
| Octapharma USA, Inc. | 1 | $23 |
| UCB, Inc. | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Alk-abello, Inc | 1 | $16 |
| Organogenesis Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$451,878
- TEZSPIRE$88,990
- AIRSUPRA$52,987
- XOLAIR$19,387
- PNEUMOVAX 23$17,214
- GARDASIL$16,335
- GARDASIL 9$16,335
- CAPVAXIVE$13,971
- NEFFY$10,146
- PREVNAR - 13$3,450
- DUPIXENT$2,364
- PREVNAR 20$1,900
- BREZTRI$372
- SAPHNELO$108
How this compares
$719,044 in reported general payments places this provider in the 90th percentile of 30 allergy & immunology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levocetirizine Dihydrochloride | 12 | $54 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Cullman
- John AndersonHomewood$3.3M
- Lawrence SindelMobile$1.3M
- Njeri MainaBirmingham$241K
- Thomas AtkinsonBirmingham$155K
- William DavidsonDaphne$98K
- Michael PolcariBirmingham$86K
- Thomas ScottBessemer$65K
- Miranda CurtissBirmingham$46K
- Karen BarkerDaphne$19K
- Robert GreerMobile$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.